Fridman WH - Search Results

1

IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.

Dorval T, Mathiot C, Chosidow O, Revuz J, Avril MF, Guillaume JC, Tursz T, Brandely M, Pouillart P, Fridman WH. Dorval T, et al. Among authors: fridman wh. Biotechnol Ther. 1992;3(1-2):63-79. Biotechnol Ther. 1992. PMID: 1305893 Clinical Trial.

2

In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors.

Mathiot C, Amigorena S, Moncuit J, Sautès C, Fridman WH, Teillaud JL. Mathiot C, et al. Among authors: fridman wh. Immunol Res. 1992;11(3-4):296-304. doi: 10.1007/BF02919135. Immunol Res. 1992. PMID: 1287123

3

Current status of interleukin-2 therapy in cancer.

Tartour E, Mathiot C, Fridman WH. Tartour E, et al. Among authors: fridman wh. Biomed Pharmacother. 1992;46(10):473-84. doi: 10.1016/0753-3322(92)90005-r. Biomed Pharmacother. 1992. PMID: 1306361 Review.

4

Interleukin-2 therapy for metastatic uveal melanoma.

Dorval T, Fridman WH, Mathiot C, Pouillart P. Dorval T, et al. Among authors: fridman wh. Eur J Cancer. 1992;28A(12):2087. doi: 10.1016/0959-8049(92)90266-5. Eur J Cancer. 1992. PMID: 1419309 Clinical Trial. No abstract available.

5

[Treatment of metastatic malignant melanoma with interleukin-2].

Dorval T, Fridman WH, Mathiot C, Sastre X, Pouillart P. Dorval T, et al. Among authors: fridman wh. Bull Cancer. 1992;79(8):781-7. Bull Cancer. 1992. PMID: 1467601 French.

6

Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2.

Dorval T, Mathiot C, Brandely M, Escande MC, Fridman WH, Pouillart P. Dorval T, et al. Among authors: fridman wh. Eur J Cancer. 1992;28(2-3):615-6. doi: 10.1016/s0959-8049(05)80107-8. Eur J Cancer. 1992. PMID: 1591084 No abstract available.

7

Inhibitory effect of monocytes on "lymphokine activated killer" (LAK) cell activity.

Weng XC, Mathiot C, Michon J, Andreu G, Lando D, Fridman WH. Weng XC, et al. Among authors: fridman wh. Cancer Detect Prev. 1991;15(3):211-5. Cancer Detect Prev. 1991. PMID: 1905581

8

Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.

Farace F, Mathiot C, Brandely M, Tursz T, Dorval T, Pouillart P, Triebel F, Hercend T, Fridman WH. Farace F, et al. Among authors: fridman wh. Clin Exp Immunol. 1990 Nov;82(2):194-9. doi: 10.1111/j.1365-2249.1990.tb05426.x. Clin Exp Immunol. 1990. PMID: 2122928 Free PMC article.

9

Involvement of FcR+ T cells and of IgG-BF in the control of myeloma cells.

Teillaud JL, Brunati S, Elmalek M, Astier A, Nicaise P, Moncuit J, Mathiot C, Job-Deslandre C, Fridman WH. Teillaud JL, et al. Among authors: fridman wh. Mol Immunol. 1990 Dec;27(12):1209-17. doi: 10.1016/0161-5890(90)90024-t. Mol Immunol. 1990. PMID: 2148806 No abstract available.

10

Problems and prospects of new immunotherapeutic approaches.

Fridman WH, Mathiot C, Michon J, Teillaud JL, Dorval T, Zucker JM, Pouillart P. Fridman WH, et al. Cancer Detect Prev. 1990;14(6):657-60. Cancer Detect Prev. 1990. PMID: 2257565 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

539 results

Search Page

Filters